Nectar Lifesciences Share Price
Nectar Lifesciences Share Price Today
As of 5 Jul 2026, Nectar Lifesciences share price is ₹11.77. The stock opened at ₹11.80, compared to its previous close of ₹11.90. During today's trading session, Nectar Lifesciences share price moved in the range of ₹11.66 to ₹11.99, with an average price of ₹11.82 for the day. Looking at its last 52-week, the stock has touched a low of ₹9.30 and a high of ₹23.38. On the performance front, Nectar Lifesciences share price has declined by 41.60% over the last six months and is down 50.02% on a year-on-year basis.
Nectar Lifesciences Returns Calculator
Nectar Lifesciences Shareholder Returns
Nectar Lifesciences Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
Nectar Lifesciences Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,669.97 | ₹1,684.09 | ₹1,523.67 | ₹1,668.83 |
| Other Income | ₹4.99 | ₹14.58 | ₹43.18 | ₹11.32 |
| Total Revenue | ₹1,674.97 | ₹1,698.66 | ₹1,566.85 | ₹1,680.15 |
| Total Expenses | ₹1,836.50 | ₹1,680.39 | ₹1,609.27 | ₹1,646.07 |
| Profit Before Tax | -₹161.53 | ₹18.27 | -₹42.42 | ₹34.08 |
| Tax | -₹47.85 | ₹13.27 | -₹18.24 | ₹9.03 |
| Profit After Tax | -₹113.68 | ₹5.00 | -₹24.18 | ₹25.05 |
| EPS - Basic | -₹5.07 | ₹0.22 | -₹1.08 | ₹1.12 |
| EPS - Diluted | -₹5.07 | ₹0.22 | -₹1.08 | ₹1.12 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | -₹161.53 | ₹18.27 | -₹42.42 | ₹34.08 |
| Income before WC changes | -₹22.51 | ₹155.82 | ₹55.73 | ₹159.55 |
| Change in Assets | ₹170.62 | -₹44.77 | ₹150.36 | -₹83.21 |
| Change in Liabilities | ₹21.33 | ₹113.63 | -₹72.43 | ₹18.67 |
| Change in WC | ₹191.95 | ₹68.87 | ₹77.93 | -₹64.54 |
| Cash flow from Operations | ₹169.44 | ₹224.69 | ₹133.65 | ₹95.01 |
| Cash flow from Investing | -₹41.93 | -₹17.03 | ₹51.70 | ₹16.64 |
| Cash flow from Financing | -₹128.09 | -₹205.44 | -₹185.58 | -₹119.38 |
| Total Cash Flow | -₹0.58 | ₹2.23 | -₹0.23 | -₹7.73 |
| Cash (Start of the year) | ₹19.81 | ₹17.58 | ₹17.81 | ₹25.54 |
| Cash (End of the year) | ₹19.22 | ₹19.81 | ₹17.58 | ₹17.81 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹809.64 | ₹907.23 | ₹958.03 | ₹1,035.98 |
| Current Assets | ₹1,237.59 | ₹1,283.83 | ₹1,231.18 | ₹1,354.85 |
| Total Assets | ₹2,047.23 | ₹2,191.06 | ₹2,189.21 | ₹2,390.83 |
| Current Liabilities | ₹1,021.54 | ₹972.82 | ₹890.93 | ₹1,003.83 |
| Net Current Asset | ₹216.05 | ₹311.02 | ₹340.26 | ₹351.02 |
| Non-Current Liabilities | ₹69.58 | ₹148.99 | ₹233.69 | ₹299.09 |
| Equity Capital | ₹956.11 | ₹1,069.25 | ₹1,064.60 | ₹1,087.91 |
| Total Equity & Liabilities | ₹2,047.23 | ₹2,191.06 | ₹2,189.21 | ₹2,390.83 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,669.97 | ₹1,684.09 | ₹1,523.67 | ₹1,668.23 |
| Other Income | ₹4.99 | ₹14.58 | ₹43.18 | ₹11.32 |
| Total Revenue | ₹1,674.97 | ₹1,698.66 | ₹1,566.85 | ₹1,679.55 |
| Total Expenses | ₹1,836.50 | ₹1,680.39 | ₹1,607.54 | ₹1,645.20 |
| Profit Before Tax | -₹161.53 | ₹18.28 | -₹40.69 | ₹34.35 |
| Tax | -₹47.85 | ₹13.27 | -₹18.24 | ₹9.03 |
| Profit After Tax | -₹113.68 | ₹5.00 | -₹22.46 | ₹25.32 |
| EPS - Basic | -₹5.07 | ₹0.22 | -₹1.00 | ₹1.13 |
| EPS - Diluted | -₹5.07 | ₹0.22 | -₹1.00 | ₹1.13 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | -₹161.53 | ₹18.28 | -₹40.69 | ₹34.35 |
| Income before WC changes | -₹22.51 | ₹155.83 | ₹56.39 | ₹159.80 |
| Change in Assets | ₹170.62 | -₹44.77 | ₹149.33 | -₹83.34 |
| Change in Liabilities | ₹21.33 | ₹113.63 | -₹72.35 | ₹18.58 |
| Change in WC | ₹191.95 | ₹68.87 | ₹76.98 | -₹64.76 |
| Cash flow from Operations | ₹169.44 | ₹224.69 | ₹133.37 | ₹95.04 |
| Cash flow from Investing | -₹41.93 | -₹17.03 | ₹52.03 | ₹16.64 |
| Cash flow from Financing | -₹128.09 | -₹205.44 | -₹185.57 | -₹119.38 |
| Total Cash Flow | -₹0.58 | ₹2.23 | -₹0.17 | -₹7.70 |
| Cash (Start of the year) | ₹19.80 | ₹17.57 | ₹17.74 | ₹25.43 |
| Cash (End of the year) | ₹19.22 | ₹19.80 | ₹17.57 | ₹17.74 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹809.65 | ₹907.23 | ₹958.04 | ₹1,035.95 |
| Current Assets | ₹1,237.58 | ₹1,283.83 | ₹1,231.18 | ₹1,353.75 |
| Total Assets | ₹2,047.23 | ₹2,191.06 | ₹2,189.21 | ₹2,389.71 |
| Current Liabilities | ₹1,021.54 | ₹972.82 | ₹890.93 | ₹1,003.75 |
| Net Current Asset | ₹216.04 | ₹311.01 | ₹340.25 | ₹350.00 |
| Non-Current Liabilities | ₹69.58 | ₹148.99 | ₹233.69 | ₹299.09 |
| Equity Capital | ₹956.11 | ₹1,069.25 | ₹1,064.60 | ₹1,086.86 |
| Total Equity & Liabilities | ₹2,047.23 | ₹2,191.06 | ₹2,189.21 | ₹2,389.71 |
About Nectar Lifesciences
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Nectar Lifesciences Financial Highlights
- Revenue: Nectar Lifesciences reported revenue of ₹9.29 crore in FY26 vs ₹1.88 crore in FY25. It showed an increase of 394.15% on a yearly basis.
- Operating Profit: Nectar Lifesciences reported an operating loss of ₹87.88 crore in FY26 vs ₹1.07 crore in FY25. It showed a decrease of 8,313.08% on a year-on-year basis.
- Net Profit: Nectar Lifesciences reported a net loss of ₹292.89 crore in FY26 vs ₹113.68 crore in FY25. It showed a decrease of 157.64% on a yearly basis.
Nectar Lifesciences Quarterly Result Highlights
- Nectar Lifesciences reported revenue of ₹7.58 crore in Mar 2026, compared with ₹0.66 crore in Dec 2025, representing an increase of 1,048.48% on a quarter-on-quarter (QoQ) basis.
- Nectar Lifesciences reported an operating loss of ₹56.93 crore in Mar 2026, compared with ₹31.55 crore in Dec 2025, representing a decrease of 80.44% on a quarter-on-quarter (QoQ) basis.
- Nectar Lifesciences reported a loss of ₹67.92 crore in Mar 2026, compared with ₹14.27 crore in Dec 2025, reflecting a decrease of 575.96% on a QoQ basis.
- The earnings per share (EPS) of Nectar Lifesciences stood at ₹5.07 during Mar 2026.
Similar Stocks
FAQs on Nectar Lifesciences Share Price
What is Nectar Lifesciences share price today?
Nectar Lifesciences share price is ₹11.77 as on 03 Jul, 2026, 15:29 IST.
How has the Nectar Lifesciences share price performed in the past?
In the last 1 year, Nectar Lifesciences delivered a return of -50.02%. The Nectar Lifesciences share price hit a high of ₹23.38 and low of ₹9.30.
How much is the Mutual Fund shareholding in Nectar Lifesciences shares?
The Mutual Fund Shareholding in Nectar Lifesciences was 0.00% at the end of Mar 2026.
What is the the 52-week high and low of Nectar Lifesciences shares ?
The 52-week high and low of Nectar Lifesciences share is ₹23.38 and ₹9.30 as of 03 Jul, 2026.
What is the market cap of Nectar Lifesciences?
The market capitalisation of Nectar Lifesciences is ₹230.20 Crores as on 03 Jul, 2026.
What are the stock symbols of Nectar Lifesciences?
The stock symbol of Nectar Lifesciences is NECLIFE on the NSE, 532649 on the BSE, and the ISIN is INE023H01027.
What was yesterday's closing price of Nectar Lifesciences shares ?
Nectar Lifesciences shares closed yesterday at ₹11.90 on NSE & ₹11.85 on BSE
How to buy Nectar Lifesciences shares?
To buy Nectar Lifesciences shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Nectar Lifesciences shares on Holidays?
No, shares of Nectar Lifesciences or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Nectar Lifesciences shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Nectar Lifesciences?
The PE and PB ratio of Nectar Lifesciences is -0.79 and 0.4 respectively, as on 03 Jul, 2026, 15:29 IST.